Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 4 × Adenocarcinoma × icotinib × Clear all

Phase

Phase 4 1 Phase 3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Carcinoma, Non-Small-Cell Lung 5 NSCLC 2 Neoplasms, Second Primary 1 Lung Neoplasms 1 Adenocarcinoma 1

Interventions

ferric carboxymaltose 2 Pemetrexed 2 Drug Therapy 2 iron isomaltoside 1000 1 icotinib 1 ferrous sulfate 1 elemene 1 aumolertinib 1 aflutinib 1 Rabeprazole 1 Gemcitabine 1 Docetaxel 1 Desflurane 1 Carboplatin 1 Albumin-Bound Paclitaxel 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02103257 2015-04-29

Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma

Betta Pharmaceuticals Co., Ltd.

Phase 4 Unknown

Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡